Key result
A review of the Cecil Textbook of Medicine from 1927 to 2020 revealed that pharmacological management of atrial fibrillation was unchanged for over 50 years before the introduction of newer agents.
Why the study?
The study sought to identify the milestone changes in expert approaches to the pharmacological management of AF over the past century.
A historical review of the Cecil Textbook of Medicine highlights that atrial fibrillation management remained stagnant for over 50 years before the advent of modern rate control, rhythm control, and anticoagulation therapies.
Answers are grounded in this paper and cite their sources.
Documents century-long AF pharmacotherapy shifts in a major textbook; leaves open alignment with contemporary trial evidence.
BACKGROUND: Advances in drug therapy for atrial fibrillation (AF) have had a significant impact on the quality of life of a substantial majority of affected persons, which has contributed to a remarkable decrease in the frequency and severity of thromboembolic complications, hospitalizations, and mortality. STUDY QUESTION: What are the milestones of the changes in the expert approach to the pharmacological management of AF in the past century? STUDY DESIGN: To determine the changes in the experts' approach to the management of AF, as presented in a widely used textbook in the United States. DATA SOURCES: The chapters presenting the management of AF in the 26 editions of Cecil Textbook of Medicine published from 1927 through 2020. RESULTS: AF was consistently described in Cecil Textbook of Medicine as the most common sustained arrhythmia in adults. The authors emphasized its thromboembolic complications and potential for hemodynamic deterioration. Rate control with digitalis and rhythm control with quinidine were the standard in 1927. The pharmacological advances have focused on atrioventricular nodal blocking for rate control, conversion to and maintenance of sinus rhythm, and preventive anticoagulation. The first new class of drugs for rate control was beta-adrenergic receptor blockers, starting with propranolol which was introduced in 1979, followed by the calcium channel blocker verapamil in 1988. Rhythm control with amiodarone, a potassium channel blocker, has been recommended since 2004, and the sodium channel blockers propafenone and flecainide became part of standard therapy in 2008. Anticoagulation with warfarin was recommended starting in 2000, followed by the introduction of direct thrombin inhibitor in 2012 and factor Xa inhibitors in 2016. CONCLUSIONS: The pharmacological management of AF was unchanged for more than 50 years (1927-1979), a period during which the devastating effects of thromboembolic complications were not addressed. The major therapeutic advance is represented by preventive anticoagulation with the newer, safer, and more user-friendly direct thrombin and factor Xa inhibitors.
No takes yet. Share an insight, caveat, or question.
Manu et al. (2022) conducted a review in Atrial fibrillation. Pharmacological management of atrial fibrillation was evaluated on Milestones of changes in expert approach to pharmacological management. A review of the Cecil Textbook of Medicine from 1927 to 2020 revealed that pharmacological management of atrial fibrillation was unchanged for over 50 years before the introduction of newer agents.
Synapse has enriched 10 related papers. Consider them for comparative context: